Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

A Study Of The Safety And Efficacy Of PF-04191834 In Patients With Osteoarthritis Of The Knee

ClinicalTrials.gov ID: NCT01147458

Public ClinicalTrials.gov record NCT01147458. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 7, 2026, 5:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Randomized, Double-Blinded, Double-Dummy, Placebo And Active Controlled Two Cohort Two-Way Cross-Over, Multi-Centre Clinical Trial To Examine The Pain Relief Produced By 2 Weeks Of Daily Oral Administration Of A 5-Lipoxygenase (5-Lox) Inhibitor PF-04191834 Alone And In Combination With Naproxen In Patients With Flare-Enriched Osteoarthritis Of The Knee

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

PF-04191834 works in animal models by inhibiting one of the enzymes, 5-lipoxygenasein which is involved in the pathway that causes inflammation and pain. The purpose of this study is to test how effective, safe and tolerated PF-04191834 is in patients with osteoarthritis of the knee by itself or with naproxen, particularly to test if patients have less pain.

Study identification

NCT ID
NCT01147458
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Pfizer
Industry
Enrollment
190 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 30, 2010
Primary completion
Jan 31, 2011
Completion
Jan 31, 2011
Last update posted
Jun 5, 2013

2010 – 2011

United States locations

U.S. sites
25
U.S. states
16
U.S. cities
23
Facility City State ZIP Site status
Pfizer Investigational Site Peoria Arizona 85381
Pfizer Investigational Site Phoenix Arizona 85013
Pfizer Investigational Site Phoenix Arizona 85015
Pfizer Investigational Site Anaheim California 92801
Pfizer Investigational Site Carmichael California 95608
Pfizer Investigational Site Fair Oaks California 95628
Pfizer Investigational Site San Diego California 92128
Pfizer Investigational Site Denver Colorado 80209
Pfizer Investigational Site DeLand Florida 32720
Pfizer Investigational Site Pensacola Florida 32504
Pfizer Investigational Site South Miami Florida 33143
Pfizer Investigational Site South Bend Indiana 46601
Pfizer Investigational Site Overland Park Kansas 66211
Pfizer Investigational Site Overland Park Kansas 66212
Pfizer Investigational Site Worcester Massachusetts 01610
Pfizer Investigational Site Edina Minnesota 55435
Pfizer Investigational Site Saint Paul Minnesota 55114
Pfizer Investigational Site Las Vegas Nevada 89144
Pfizer Investigational Site Monroe North Carolina 28112
Pfizer Investigational Site Fargo North Dakota 58103
Pfizer Investigational Site Columbus Ohio 43213
Pfizer Investigational Site Oklahoma City Oklahoma 73112
Pfizer Investigational Site Philadelphia Pennsylvania 19139
Pfizer Investigational Site Austin Texas 78705
Pfizer Investigational Site Arlington Virginia 22205

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01147458, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 5, 2013 · Synced Sep 7, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01147458 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →